FDA’s top vaccine official leaves post after less than four months | Trump administration
A government spokesman, the best vaccine official of the US Food and Pharmaceutical Administration (FDA), abandoned the federal agency in less than four months as a section that controls biological products such as Vinay Prasad, blood, vaccines and cellular and gene therapies.
San Francisco, Prasad, an oncologist at the University of California and a professor of epidemiology, bioistatistics and medicine, had previously criticized the FDA.
He was a violent critic of the US COVİD-19 vaccine and mask requirements, and in May of the FDA, under the administration of Trump Second, was appointed as the director of the Biology Evaluation and Research Center in May.
“Dr Prasad did not want to distract the FDA’s great work and decided to return to California and spend more time with his family, Revishare Endpoints News first reported that Prasad was separated.
The government did not give any details about the reason for its separation, but there were severe critics on both sides of the political corridor and Washington Post. reportedWithout responding to the requests for comments from Prasad, by referring to anonymous resources, transferred by conservative sounds in the middle of the protests.
Output, recently came after a series of unusual regulatory action, including those received by Sarepta Therapeutics’s gene therapy agency.
“There was more than one press leakage that negatively affected the FDA. [the drug’s] Reliability, B BMO Capital Markets Analyst Kostas Bilouris.
During the short period of Prasad’s Post, he limited the use of FDA COVİD-19 vaccines and refused to approve the treatments from Biotechnology Companies, looking for green light for advanced melanomas.
Jeferveries Analyst Roger Song said that the regulator’s decisions under Prasad expressed his concerns about the choice of patient analysts.
There were stocks of biotechnology immersed With the news that Prasad was appointed in May. The NASDAQ biotechnology index decreased by 7%, but later healed. Repimmune shares increased by 58%, Sarepta 11.2% and Capricor added 21.2% in pre -Sunday transactions on Wednesday.
According to Stat News, Prasad played the additional role of the chief medical and scientific officer of the agency he was appointed last month.
Bilouris said that nominating a more experienced official to change it to change the reliability of the FDA.
